Avanos Medical, Inc. (AVNS)
NYSE: AVNS · Real-Time Price · USD
13.79
-0.09 (-0.65%)
At close: Mar 5, 2026, 4:00 PM EST
14.10
+0.31 (2.25%)
After-hours: Mar 5, 2026, 7:00 PM EST
Avanos Medical Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Avanos Medical.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Avanos Medical.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 7, 2024 |
| Keybanc | Keybanc | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jul 25, 2023 |
| Stifel | Stifel | Hold Reiterates $25 | Hold | Reiterates | $25 | +81.29% | Jun 21, 2023 |
| CL King | CL King | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +124.80% | May 22, 2023 |
| Morgan Stanley | Morgan Stanley | Sell Maintains $28 → $26 | Sell | Maintains | $28 → $26 | +88.54% | May 4, 2023 |
Financial Forecast
Revenue This Year
724.20M
from 701.20M
Increased by 3.28%
Revenue Next Year
754.80M
from 724.20M
Increased by 4.23%
EPS This Year
1.02
from -1.57
EPS Next Year
1.28
from 1.02
Increased by 24.98%
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 745.5M | 777.0M |
| Avg | 724.2M | 754.8M |
| Low | 695.8M | 725.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 6.3% | 7.3% |
| Avg | 3.3% | 4.2% |
| Low | -0.8% | 0.1% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | 1.05 | 1.31 |
| Avg | 1.02 | 1.28 |
| Low | 0.98 | 1.23 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | 28.7% |
| Avg | - | 25.0% |
| Low | - | 20.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.